Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC
Nuvectis Pharma (NASDAQ: NVCT) has announced new research findings from the Cleveland Clinic demonstrating enhanced efficacy when combining their drug NXP900 with osimertinib (Tagrisso®) in treating EGFR-mutated non-small cell lung cancer (NSCLC).
The study, published in Molecular Cancer Research (2025), showed that the combination therapy was superior to osimertinib alone in vivo, resulting in decreased cell proliferation and increased apoptosis in vitro. This research validates previous findings from AstraZeneca showing NXP900's ability to reverse osimertinib resistance in resistant cell lines.
The company is approaching completion of its Phase 1a dose escalation study for NXP900 and plans to initiate a Phase 1b program, exploring opportunities both as a standalone treatment and in combination with existing anti-cancer medications.
Nuvectis Pharma (NASDAQ: NVCT) ha annunciato nuovi risultati di ricerca provenienti dalla Cleveland Clinic che dimostrano un'efficacia migliorata combinando il loro farmaco NXP900 con osimertinib (Tagrisso®) nel trattamento del carcinoma polmonare non a piccole cellule (NSCLC) con mutazione EGFR.
Lo studio, pubblicato su Molecular Cancer Research (2025), ha mostrato che la terapia combinata era superiore a osimertinib da solo in vivo, risultando in una diminuzione della proliferazione cellulare e un aumento dell'apoptosi in vitro. Questa ricerca convalida i risultati precedenti di AstraZeneca che mostrano la capacità di NXP900 di invertire la resistenza a osimertinib in linee cellulari resistenti.
L'azienda sta per completare il suo studio di escalation della dose di Fase 1a per NXP900 e prevede di avviare un programma di Fase 1b, esplorando opportunità sia come trattamento autonomo che in combinazione con farmaci anti-cancro esistenti.
Nuvectis Pharma (NASDAQ: NVCT) ha anunciado nuevos hallazgos de investigación de la Cleveland Clinic que demuestran una eficacia mejorada al combinar su medicamento NXP900 con osimertinib (Tagrisso®) en el tratamiento de cáncer de pulmón no microcítico (NSCLC) con mutación EGFR.
El estudio, publicado en Molecular Cancer Research (2025), mostró que la terapia combinada era superior a osimertinib solo in vivo, resultando en una disminución de la proliferación celular y un aumento de la apoptosis in vitro. Esta investigación valida hallazgos previos de AstraZeneca que muestran la capacidad de NXP900 para revertir la resistencia a osimertinib en líneas celulares resistentes.
La empresa está cerca de completar su estudio de escalada de dosis de Fase 1a para NXP900 y planea iniciar un programa de Fase 1b, explorando oportunidades tanto como tratamiento independiente como en combinación con medicamentos anticancerígenos existentes.
누벡티스 제약 (NASDAQ: NVCT)은 클리블랜드 클리닉의 새로운 연구 결과를 발표했으며, 이 연구는 그들의 약물 NXP900과 오시머티닙(Tagrisso®)을 결합하여 EGFR 변이가 있는 비소세포 폐암 (NSCLC) 치료 시 효과가 향상됨을 보여줍니다.
2025년에 Molecular Cancer Research에 발표된 이 연구는 결합 요법이 in vivo에서 단독 오시머티닙보다 우수하며, in vitro에서 세포 증식 감소와 세포 사멸 증가를 초래함을 보여주었습니다. 이 연구는 NXP900이 저항성 세포주에서 오시머티닙 저항성을 역전시키는 능력을 보여준 아스트라제네카의 이전 연구 결과를 검증합니다.
회사는 NXP900에 대한 1a 단계 용량 증가 연구를 마무리하고 있으며, 기존 항암제와의 병용 및 단독 치료로서의 기회를 탐색하는 1b 단계 프로그램을 시작할 계획입니다.
Nuvectis Pharma (NASDAQ: NVCT) a annoncé de nouvelles découvertes de recherche provenant de la Cleveland Clinic, démontrant une efficacité accrue en combinant leur médicament NXP900 avec osimertinib (Tagrisso®) pour traiter le cancer du poumon non à petites cellules (NSCLC) avec mutation EGFR.
L'étude, publiée dans Molecular Cancer Research (2025), a montré que la thérapie combinée était supérieure à l'osimertinib seul in vivo, entraînant une diminution de la prolifération cellulaire et une augmentation de l'apoptose in vitro. Cette recherche valide les résultats précédents d'AstraZeneca montrant la capacité de NXP900 à inverser la résistance à l'osimertinib dans des lignées cellulaires résistantes.
L'entreprise est sur le point de terminer son étude d'escalade de dose de phase 1a pour NXP900 et prévoit de lancer un programme de phase 1b, explorant des opportunités à la fois en tant que traitement autonome et en combinaison avec des médicaments anticancéreux existants.
Nuvectis Pharma (NASDAQ: NVCT) hat neue Forschungsergebnisse der Cleveland Clinic bekannt gegeben, die eine verbesserte Wirksamkeit bei der Kombination ihres Medikaments NXP900 mit Osimertinib (Tagrisso®) zur Behandlung von EGFR-mutiertem nicht-kleinzelligem Lungenkrebs (NSCLC) zeigen.
Die Studie, veröffentlicht in Molecular Cancer Research (2025), zeigte, dass die Kombinationstherapie in vivo überlegen war im Vergleich zu Osimertinib allein, was zu einer verringerten Zellproliferation und einer erhöhten Apoptose in vitro führte. Diese Forschung bestätigt frühere Ergebnisse von AstraZeneca, die die Fähigkeit von NXP900 zeigen, die Osimertinib-Resistenz in resistenten Zelllinien umzukehren.
Das Unternehmen steht kurz vor dem Abschluss seiner Phase 1a Dosissteigerungsstudie für NXP900 und plant, ein Phase 1b-Programm zu starten, um sowohl als eigenständige Behandlung als auch in Kombination mit bestehenden Krebsmedikamenten Möglichkeiten zu erkunden.
- Phase 1a dose escalation study nearing completion
- Successful validation of drug efficacy by independent research institution
- Demonstrated ability to reverse drug resistance in cancer treatment
- Potential dual revenue streams (standalone and combination therapy)
- Still in early clinical development phases
- No efficacy data from human trials reported yet
Research conducted at the Lerner Research Institute, Cleveland Clinic (at Case Western Reserve University)
Fort Lee, NJ, March 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced a new publication from the laboratory of Prof. Ruth Keri, (Cleveland Clinic, Cleveland, OH, USA) demonstrating that the combination of NXP900 and osimertinib (the active ingredient in Tagrisso®) was superior to single agent osimertinib in vivo in a model of Epidermal Growth Factor Receptor(EGFR) mutated non-small cell lung cancer (NSCLC), and led to decreased cell proliferation and increased apoptosis in vitro. The data reported in this new publication (Cuellar-Vite et al., Molecular Cancer Research, 2025; DOI: 10.1158/1541-7786.MCR-24-030) further supports the mechanistic rationale for the combination of NXP900 and EGFR inhibitors in EGFR-mutated tumors, and further validates the data previously published by the research team at Astra Zeneca which demonstrated that the addition of NXP900 to osimertinib reverses resistance to osimertinib in osimertinib resistant cell lines.
Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “As we continue our activities toward the initiation of the Phase 1b program of NXP900, we are very pleased to see yet another independently generated dataset from a highly reputable research institution demonstrating the synergistic effect of adding NXP900 to osimertinib in EGFR mutated NSCLC. With the Phase 1a dose escalation study nearing completion, we are excited about the potential opportunities presented by NXP900 in therapeutic areas of unmet medical need, both as a single agent and in combination with market-leading anti-cancer drugs.”
About Nuvectis Pharma
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900's unique mechanism of action enables the inhibition of both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties, including statements regarding the expected and intended use of proceeds from the offering. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including statements regarding the intended. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Nuvectis Pharma, Inc.'s current expectations, including estimates and projections about future events and trends that we believe may affect our business, financial condition, results of operations, prospects, business strategy, and financial needs. The outcome of the events described in these forward-looking statements are subject to inherent uncertainties, risks, assumptions, market and other conditions, and other factors that are difficult to predict and include statements regarding the preclinical studies for NXP900 and statements regarding NXP900's therapeutic potential and the expected timing for the completion of the Phase 1a dose-escalation study and start of the NXP900 Phase 1b program. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are subject to market and other conditions and described more fully in the section titled "Risk Factors" in our Form 10-K and our other public filings with the Securities and Exchange Commission ("SEC"). However, these risks are not exhaustive and new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this press release or other filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Company Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
Tel: 201-614-3151
rbentsur@nuvectis.com
Media Relations Contact
Christopher M. Calabrese
LifeSci Advisors
Tel: 917-680-5608
ccalabrese@lifesciadvisors.com
FAQ
What are the key findings of the new NXP900 study for NVCT stock?
What is the current development stage of Nuvectis Pharma's (NVCT) NXP900 drug?
How does NVCT's NXP900 interact with osimertinib in cancer treatment?
What potential market opportunities does NVCT's NXP900 present?
